市场调查报告书
商品编码
1520624
动物用疼痛管理的全球市场的评估:各产品类型,各用途,各动物类型,各终端用户,各地区,机会,预测,2017年~2031年Veterinary Pain Management Market Assessment, By Product, By Application, By Animal Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
2024-2031年预测期间,全球兽医疼痛管理市场规模将以复合年增长率6.36%扩大,从2023年的18.5亿美元增至2031年的30.4亿美元。该市场已经经历了相当大的成长,预计未来将以多种方式扩张,呈现出作为利润丰厚的投资机会的潜力。
用于缓解动物疼痛并确保舒适度和生活品质的过程和疗法称为兽医疼痛管理。其广泛的应用包括透过使用镇痛药、抗发炎药物、物理治疗以及针灸和雷射疗法等替代疗法来治疗由手术、慢性病、损伤和其他医疗状况引起的疼痛。为了让动物感到舒适和无痛,主人越来越关注动物福利,从而增加了对疼痛管理产品和服务的需求。
然而,许多宠物主人仍然没有意识到控制宠物疼痛的重要性。这种无知可能会导致诊断不足和治疗不足,从而损害宠物的健康。由于相对成本,宠物主人可能难以购买兽医疼痛管理产品和服务,尤其是在欠发达地区。有些止痛药可能会产生有害作用,对动物造成危险。兽医行业缺乏疼痛管理专家,这可能限制了获得专业疼痛管理服务的机会。开发和批准兽用止痛药物需要满足严格的监管标准,这既昂贵又耗时。与针灸和草药等传统疼痛管理产品和服务相比,宠物主人越来越喜欢替代疗法。这可能会对市场扩张产生正面影响。兽医疼痛管理有很多好处,对动物的健康和福祉至关重要。
由于全球宠物饲养趋势,兽医疼痛治疗市场正在扩大。随着养宠物家庭数量的增加,对兽医医疗服务,特别是疼痛管理的需求不断增加。随着宠物主人越来越意识到他们的动物的健康和福利,越来越多的人开始向兽医寻求治疗急性和慢性疼痛疾病。由于知识的增加,越来越多的人定期去兽医诊所,因此疼痛管理受到了频繁的关注。对于宠物的关节炎、手术疼痛和与年龄相关的不适等疾病,有效的疼痛管理是必要的。因此,兽医医院和诊所正在扩大其提供的疼痛治疗范围,从药物到物理治疗。
本报告提供全球动物用疼痛管理市场相关调查,提供市场概要,以及各产品类型,各用途,各动物类型,各终端用户,各地区趋势,及加入此市场的主要企业简介等资讯。
Global veterinary pain management market is projected to witness a CAGR of 6.36% during the forecast period 2024-2031, growing from USD 1.85 billion in 2023 to USD 3.04 billion in 2031. The market has seen considerable growth and is poised for further manifold expansion in the future, indicating its potential as a profitable investment opportunity. The processes and therapies used to relieve pain in animals while ensuring their comfort and quality of life is referred to as veterinary pain management. It encompasses a broad range of uses, including the management of pain brought on by surgeries, chronic illnesses, injuries, and other medical conditions through the use of analgesics, anti-inflammatory drugs, physical therapy, and alternative therapies like acupuncture and laser therapy. In order to keep their animals comfortable and pain-free, pet owners are becoming more conscious of animal welfare, which has raised demand for pain management products and services. Still, a lot of pet owners do not yet realize the importance of managing their pets' suffering. This ignorance may result in underdiagnosis and undertreatment, which could be detrimental to their pet's health. Pet owners may find it difficult to afford veterinary pain management goods and services, especially in underdeveloped regions, due to their comparatively high cost. Certain painkillers may have adverse consequences that are dangerous to animals. The veterinary industry is experiencing a scarcity of pain management professionals, which may restrict access to specialized pain management services. Strict regulatory standards must be met for pain management medications intended for veterinary use to be developed and approved, which can be expensive and time-consuming. Pet owners are starting to favor alternative therapies over conventional pain management goods and services, such as acupuncture and herbal medications. This may have a positive effect on market expansion. Veterinarian-assisted pain management has many benefits and is crucial to preserving animal's health and well-being.
As a platinum sponsor, Norbrook Laboratories Limited supported the International Society of Feline Medicine (ISFM) Congress in Dublin in June 2023. Veterinarians and nurses receive the information they need from the International Society of Feline Medicine (ISFM) to effectively address health issues in cats. Their annual congress was held in Dublin, and Norbrook Laboratories Limited was well-represented, emphasizing Thyronorm and Loxicom, their two primary cat products.
Rising Pet Ownership Leading to Market Expansion
The market for veterinary pain treatment is expanding due to the growing trend of pet ownership around the world. The need for veterinary services, particularly pain management, is rising in tandem with the number of households adopting pets. More people are turning to veterinarians for both acute and chronic pain disorders as a result of growing pet owners' awareness of the health and welfare of their animals. There has been an increase in regular veterinary visits as a result of this increased knowledge, and thus, pain management frequently becomes a point of focus. Effective pain management is necessary for conditions like arthritis, surgical pain, and age-related discomfort in pets. As a result, veterinary hospitals and clinics are broadening the scope of pain treatment services they provide, ranging from medication to physical therapy. Additionally, developments in veterinary medicine have enhanced diagnostic capacities, enabling earlier identification and more accurate management of pain. Since there is a deep emotional connection to their dogs, pet owners are prepared to spend money on cutting-edge pain relief techniques in order to prolong the lives of their pets. Innovations in pain management products, such as opioids, nonsteroidal anti-inflammatory medications (NSAIDs), nutraceuticals, and complementary therapies like laser and acupuncture, are also helping the industry. The availability of these varied alternatives gives vets the instruments required to customize pain management programs for specific animals, improving the results of treatment. The humanization of pets, in which animals are considered members of the family, also increases the need for superior veterinarian care. Given that pet owners are looking for thorough and sympathetic care for their animal companions, it is anticipated that this cultural shift will both sustain and accelerate the growth of the veterinary pain treatment industry.
For example, the acquisition of Ethos Veterinary Health by National Veterinary Associates (NVA) Compassion-First, which happened in 2023, illustrates how the expanding pet ownership trend is impacting the veterinary pain care sector. The increased need for specialized veterinary services, including pain management, is reflected through this acquisition. Expanding its offerings to incorporate Ethos's advanced pain management and specialist care, National Veterinary Associates Compassion-First, a network of more than 1,000 veterinary institutions, demonstrated the industry's response to the growing need for comprehensive pet healthcare brought on by the rise in pet ownership.
Huge Investments in Petcare Segment to Spur Market Growth
The veterinary pain management industry is growing at a high rate due to rising investments in pet care. Similar to developments in human healthcare, the demand for advanced healthcare services for pets is rising along with the number of pet owners. Pet owners are becoming more and more prepared to invest in their pets' health, which is driving up the number of veterinary appointments and operations that require efficient pain management techniques. Innovations in veterinary technology have resulted in the creation of novel and enhanced pain relief items, encompassing medications, nutritional plans, and medical apparatus. The increasing accessibility of these advancements prompts vets to implement more thorough pain management procedures, enhancing the standard of care and prolonging the lives of their patients. Furthermore, veterinary associations and animal welfare organizations' educational activities have raised public awareness about animal suffering and pain. This increased awareness prompts pet owners to look for prompt and efficient pain management solutions for their animals, which fuels the market's expansion even more. Insurance providers are also very important as these services are now more widely available to a larger audience because of growth of pet insurance policies that include coverage for pain management therapies. Pet owners have less financial strain because of this financial assistance, which motivates them to choose better pain management products. Long-term therapy solutions are in high demand since chronic illnesses, including cancer, arthritis, and post-surgical pain in dogs, are becoming more common and require constant pain management. Pharmaceutical companies are, therefore, making significant investments in R&D to produce safer and more effective animal analgesics. In conclusion, the market for veterinary pain management is expected to rise at a solid rate due to the convergence of rising chronic illness prevalence, increased awareness, expanding insurance coverage, and technological advancements.
For instance, leading animal health business, Zoetis Services LLC, introduced Solensia, a monoclonal antibody, in 2022 to help cats with osteoarthritis pain management. This cutting-edge product perfectly captures how the veterinary pain management business has been impacted by rising investments in pet healthcare. Through cutting-edge therapeutic solutions, Zoetis drove market growth by addressing a huge unmet need and offering a fresh, long-lasting pain management option.
Dominance of the NSAIDs Segment Drives Market Growth
In terms of revenue, nonsteroidal anti-inflammatory drugs (NSAIDs) hold the biggest market share and are predicted to grow at a notable CAGR during the forecast period. These medications are essential for the treatment of many different pain-related conditions in animals, including cancer and arthritis, as well as acute trauma and post-operative recovery. The best pain relief is provided by analgesics, which include both opioid and non-opioid painkillers. On the other hand, nonsteroidal anti-inflammatory drugs (NSAIDs) help to reduce inflammation and relieve pain brought on by several disorders. The need for these medications has grown as a result of the increasing frequency of these excruciating and inflammatory diseases in animals and pets, propelling market expansion. The increasing use of analgesic and anti-inflammatory drugs is indicative of a growing recognition among veterinarians and pet owners of the importance of pain management for the health and welfare of animals. More people are looking for holistic treatment for their pets, including effective pain management techniques, as the number of pet owners globally rises. Since untreated pain can significantly affect an animal's quality of life and general health, veterinarians are also taking an active approach to identifying and treating animal pain. Growing consumer knowledge is encouraging the use of a variety of painkillers, which is driving the market's expansion. Additionally, major players' endeavors, such as the introduction of new products, are accelerating the market's growth.
For example, Krka, tovarna zdravil, d.d., Novo mesto introduced Robexera, the first generic version of robenacoxib, in November 2023 to treat pain and inflammation in dogs resulting from soft tissue surgery and persistent osteoarthritis (OA).
North America Dominates the Veterinary Pain Management Market
North America holds the largest market share in the veterinary pain management market. This is because of the well-established veterinary healthcare infrastructure, the widespread use of cutting-edge technology, high disposable income, and the existence of significant businesses. These businesses' strategic actions keep boosting the expansion of the regional market. In April 2022, Zoetis Services LLC introduced AI blood smear testing for dogs and cats, enhancing its Vetscan Imagyst platform. Furthermore, the market under study is expanding due to the growing number of veterinary practitioners. For example, the U.S. Bureau of Labor Statistics stated in September 2022 that employment of veterinarians is expected to expand by 19% between 2021 and 2031, which is substantially greater than the average growth rate of all occupations. Additionally, according to the same source, there will be 4,800 expected openings for veterinarians annually on average during the next ten years. Hence, the growing number of veterinarians is fueling the demand for veterinary pain management services, which in turn is propelling the market under study's expansion. One of the main factors propelling market revenue growth in this region is the growing number of government efforts encouraging students to work in the veterinary health industry. For example, Ohio State's MPH-VPH veterinary healthcare program equips students with the public health credentials necessary to oversee zoonotic disease prevention and control initiatives across the nation.
Future Market Scenario (2024-2031F)
The main factors contributing to the anticipated growth of the veterinary pain management market are the rising pet ownership, increasing prevalence of zoonotic diseases, and thus, the rising requirement for pain management services. However, the growing need to have precision medicine to maintain healthy livestock animals and pets is also going to fuel the market growth in the future. Given that technology is advancing, cutting-edge technology in the field is expected to be developed. Players in this market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies. Government policies and policies made by welfare bodies are also greatly fueling the market expansion. For instance, PepiPets, Inc. launched a new mobile diagnostic testing service in August 2022. Its users were able to conduct diagnostic testing for their pets at home after the new service was introduced, according to a business announcement. Pets were supposed to feel more at ease with the treatment and spend less time traveling to an in-person office visit due to PepiPets Inc.'s at-home testing service.
Key Players Landscape and Outlook
Several companies such as Zoetis Services LLC, Boehringer Ingelheim Animal Health USA Inc., Vetoquinol, Dechra Veterinary Products Limited, Merck & Co., Inc., Ceva Sante Animale, Norbrook Laboratories Limited, Chanelle Pharma Group Ltd., Fear Free, LLC, Elanco, etc. are expanding business by planning and adopting new strategies. They are complying with new strategic initiatives regarding the launch of newly developed veterinary pain management services, to help researchers and to strengthen their presence in the market. New product launches, agreements based on contracts, acquisitions and mergers, investments, and partnerships are a few ways through which they are trying to achieve the same.
For instance, with the establishment of its 35th VirbacGroup subsidiary, VirbacGroup finished acquiring all the shares of its previous distributor in Slovakia and the Czech Republic in May 2023. The teams under the direction of Jakub Satrapa, the company's previous owner and general manager of the upcoming subsidiary, worked hard for years to achieve this purchase. Their new VirbacGroup subsidiary would enable them to respond to the health needs of animals in Slovakia and the Czech Republic more quickly and efficiently.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.